Other abnormalities may be found in latter and aggressive stages of MM, mainly gene mutations involving gain of function of oncogenes such as NRAS, KRAS, BRAF and CCND1, loss of function of tumor suppressors like p53, RB1, DIS3, CDKN2A and CDKN2C, and mutations in the NF-κB and STAT3 pathways. This evidence concerns the gene NFKB1 and Miyoshi myopathy.